Results 331 to 340 of about 393,592 (390)

Proteasomes and Ubiquitin C-Terminal Hydrolase L1 as Biomarkers of Tissue Damage and Inflammatory Response to Different Types of Injury-A Short Review. [PDF]

Life (Basel)
Tylicka M, Matuszczak E, Kamińska J, Modzelewska B, Koper-Lenkiewicz OM.   +4 more
europepmc   +1 more source

Modulation of CREB3L2-ATF4 heterodimerization via proteasome inhibition and HRI activation in Alzheimer's disease pathology. [PDF]

Cell Death Dis
Herline-Killian K, Pauers MM, Lipponen JE, Zrzavy MA, Gouveia Roque C, McCurdy EP, Chung KM, Hengst U.   +7 more
europepmc   +1 more source

ISGylation and E3 ubiquitin ligases: an Atlantic salmon genetic perspective. [PDF]

Front Immunol
Grimholt U, Sindre H, Sundaram AYM.
europepmc   +1 more source

NRF1 coordinates mitochondrial adaptations to dampen intracellular ROS and inflammatory responses during ischemia reperfusion. [PDF]

Cell Death Discov
Li J, Yan J, Tu G, Jiang W, Qiu Y, Su Y, Miao C, Luo Z, Horng T.   +8 more
europepmc   +1 more source

The Role of the Ubiquitin System in Eye Diseases. [PDF]

Life (Basel)
Durán-Cristiano SC, de Diego-García L, Martín-Gil A, Carracedo G.   +3 more
europepmc   +1 more source

Structural basis for the ubiquitin chain recognition of the human 26S proteasome

Amann SJ, Kalis R, Fottner M, Knaudt H, Grishkovskaya I, Zuber J, Lang K, Brown NG, Brown NG, Haselbach D.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Stress- and ubiquitylation-dependent phase separation of the proteasome

Nature, 2020
Janet E Pope, Qiang Guo, Shigeo Murata
exaly   +2 more sources

The proteasome and proteasome inhibitors in multiple myeloma

Cancer and Metastasis Reviews, 2017
Proteasome inhibitors are one of the most important classes of agents to have emerged for the treatment of multiple myeloma in the past two decades, and now form one of the backbones of treatment. Three agents in this class have been approved by the United States Food and Drug Administration-the first-in-class compound bortezomib, the second-generation
S. Gandolfi, J. Laubach, T. Hideshima, D. Chauhan, K. Anderson, P. Richardson   +5 more
semanticscholar   +3 more sources

The ubiquitin‐proteasome pathway and proteasome inhibitors [PDF]

Medicinal Research Reviews, 2001
AbstractThe ubiquitin‐proteasome pathway has emerged as a central player in the regulation of several diverse cellular processes. Here, we describe the important components of this complex biochemical machinery as well as several important cellular substrates targeted by this pathway and examples of human diseases resulting from defects in various ...
Craig M Crews, Kyung Bo Kim
exaly   +5 more sources